Genmab's Epcoritamab Shows PFS Benefit in DLBCL Trial, OS Falls Short
Event summary
- Genmab announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab (EPKINLY®/TEPKINLY®) as monotherapy.
- The trial demonstrated a statistically significant improvement in progression-free survival (PFS) with a hazard ratio (HR) of 0.74 (95% CI: 0.60-0.92).
- Overall survival (OS) showed a HR of 0.96 (95% CI: 0.77-1.20), failing to reach statistical significance.
- The study enrolled 483 patients with relapsed/refractory DLBCL ineligible for HDT-ASCT, comparing epcoritamab to standard chemotherapy regimens (R-GemOx, BR).
The big picture
The EPCORE DLBCL-1 results represent a significant step forward for bispecific antibody therapies in DLBCL, a market with approximately 25,000 new cases annually in the U.S. While the PFS benefit is encouraging, the lack of OS significance introduces uncertainty. Genmab and AbbVie's collaboration faces the challenge of demonstrating a comprehensive benefit profile to secure broad adoption and maximize the commercial potential of epcoritamab, especially given the competitive landscape of existing therapies.
What we're watching
- Regulatory Approval
- The engagement with regulatory authorities will be critical; the lack of statistical significance in OS could influence the speed and scope of potential approvals.
- Clinical Trial Data
- The full trial results, including detailed subgroup analyses, will reveal the impact of factors like the pandemic and newer therapies on the observed outcomes.
- Pipeline Progression
- The success of the EPCORE DLBCL-2 and EPCORE DLBCL-4 trials, particularly the combination with R-CHOP, will be key to establishing epcoritamab’s broader role in DLBCL treatment.
Related topics